Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma
In the study, “Neoadjuvant Chemotherapy in High-Grade Myxoid Liposarcoma: Results of the Expanded Cohort of a Randomized Trial From Italian (ISG), Spanish (GEIS), French (FSG), and Polish Sarcoma Groups (PSG),” continues from previous research investigating neoadjuvant standard (S) anthracycline + ifosfamide (AI) treatment with histology tailored (HT) regimen in selected localized high-risk soft tissue sarcoma (STS). A previous trial demonstrated the superiority of the standard treatment in all STS histologies except for high-grade myxoid liposarcoma (HG-MLPS) where the treatments appeared to be equivalent. This study included additional patients with HG-MLPS to further investigate the two treatments. A total of 101 patients with HG-MLPS were randomly assigned, 45 to HT and 56 to S. At 60 months, the disease-free survival and overall survival were not significantly different, confirming that trabectedin is not inferior to AI as suggested in the original study. These results indicate that trabectedin may be an alternative to standard AI in HG-MLPS of the extremities or trunk when neoadjuvant treatment is appropriate.